Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risdiplam effectiveness in spinal muscular atrophy patients older than 25 years
NL-OMON61218Phase 4Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risdiplam in spinal muscular atrophy (SMA), sponsored by University Medical Center Utrecht. Primary endpoint: Change in Revised Upper Limb Module. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON61218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61218.